November 16, 2020
IBRI RESEARCH PUBLISHED: Enzyme Immunoassay-Based Platform for Accurate Detection of Serum Pathological a-Synuclein in Parkinson’s Disease Patients
Abstract
An assay for accurately diagnosing early stage Parkinson’s Disease (PD) is currently unavailable, and therefore, there is an urgent and unmet need. Such a diagnostic assay will enable...
November 12, 2020
IBRI IN THE NEWS: Biosciences Research Institute Adds Board Members
The Indiana Biosciences Research Institute has added eight members to its board of directors, including Bob Bernhard (pictured) and Wendy Srnic (pictured). Bernhard serves as vice president for research at...
November 11, 2020
IBRI RESEARCH PUBLISHED: YIPF5 Mutations Cause Neonatal Diabetes and Microcephaly through Endoplasmic Reticulum Stress
Abstract
Neonatal diabetes is caused by single gene mutations reducing pancreatic β cell number or impairing β cell function. Understanding the genetic basis of rare diabetes subtypes highlights fundamental...
November 09, 2020
Indiana Biosciences Research Institute Names New Board Members
Indianapolis, Ind. – The Indiana Biosciences Research Institute (IBRI), a leading industry-inspired applied research institute, is pleased to announce the addition of eight members to its Board of Directors. Its...
November 02, 2020
IBRI IN THE NEWS: The Dialogue of Diabetes
Over the past 60 years, the incidence of type I diabetes in parts of the word has increased sixfold, and we don’t know why. In the Eizirik Lab at the...
October 26, 2020
IBRI RESEARCH PUBLISHED: Utilization of Electronic Health Records for the Assessment of Adiponectin Receptor Autoantibodies during the Progression of Cardio-metabolic Comorbidities
Abstact
Background : Diabetes is a complex, multi-symptomatic disease whose complications drives increases in healthcare costs as the diabetes prevalence grows rapidly world-wide. Real-world electronic health records (EHRs) coupled...
October 20, 2020
IBRI RESEARCH PUBLISHED: SARS-CoV-2 receptor Angiotensin I-Converting Enzyme type 2 (ACE2) is expressed in human pancreatic ß-cells and in the human pancreas microvasculature
Abstract
Increasing evidence demonstrated that the expression of Angiotensin I-Converting Enzyme type 2 (ACE2), is a necessary step for SARS-CoV-2 infection permissiveness. In the light of the recent data...
October 01, 2020
IBRI RESEARCH PUBLISHED: Beta Cell Imaging—From Pre-Clinical Validation to First in Man Testing
Abstract
There are presently no reliable ways to quantify human pancreatic beta cell mass (BCM) in vivo, which prevents an accurate understanding of the progressive beta cell loss in...
September 18, 2020
IBRI IN THE NEWS: New Chief Wants to Grow IBRI's Global Reputation
Indianapolis - The new chief executive officer of the Indiana Biosciences Research Institute in Indianapolis says he wants to see the institute emerge as a global leader of innovative science...
September 15, 2020
IBRI RESEARCH PUBLISHED: Molecular Footprints of the Immune Assault on Pancreatic Beta Cells in Type 1 Diabetes
Abstract
Type 1 diabetes (T1D) is a chronic disease caused by the selective destruction of the insulin-producing pancreatic beta cells by infiltrating immune cells. We presently evaluated the transcriptomic...
1 2 3 4 5 ... Last